Lv1
20 积分 2024-10-21 加入
A multicenter, randomized, double-blinded, placebo-controlled, phase Ⅲ study evaluating the efficacy and safety of Xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis
2小时前
已完结
Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis
3小时前
已完结
Current treatment of Psoriasis triggered by Cytokine Storm and future immunomodulation strategies
3个月前
已完结
皖公网安备34019202002308
